GlobeNewswire

VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour

Dela

Customers to join the most prestigious worldwide polo tournament

LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, will be offering customers the opportunity to enrich their passion for polo as the company partners with British Polo Day for the 2018 worldwide tournament, following a successful inaugurate partnership last year.

The sport is a key interest for many of VistaJet's customers, both as spectators and riders, and is in line with 39% of the world's animal-loving Ultra High Net Worth population having a passion for horses*. VistaJet continuously develops and offers exceptional experiences for its customers inspired by their true passions, including art, sport and travel, across all cultures worldwide. Its global partnership with British Polo Day will offer customers an exclusive opportunity to enjoy one of their most cherished interests by watching some of the sport's top players, including the world's number one player Adolfo Cambiaso, in the most spectacular and iconic settings, such as the enchanting Umaid Bhawan Palace in Jodhpur.

"Our customers expect the most extraordinary experiences at the highest standards," explains Ian Moore, Chief Commercial Officer at VistaJet. "Our customers' passions become our passions and supporting them is a cornerstone of the VistaJet brand. In partnering on such opportunities with British Polo Day, we are able to continue to deliver second-to-none events to our community."

Originating in ancient Persia, polo has been played for over 2,600 years with the modern game beginning in Northeastern India in 1859. From there, polo spread as widely as its enthusiasts across Europe, South America, Asia and Australia. On a trip to England, the publisher James Gordon Bennett Jr. experienced his first polo match, and upon returning to his native New York in 1876, the game soon spread across North America.

British Polo Day was founded around the idea of reviving the great amateur traditions that spread the modern game of polo. Founded in Dubai in 2009, building relationships around a global community through a series of distinct experiences in iconic destinations has defined British Polo Day since inception.

VistaJet will offer customers the opportunity to travel to all British Polo Day's exclusive 2018 fixtures, starting in Abu Dhabi on 24th March and then onto Dubai, New York, Henley-upon-Thames near London and Beijing, before culminating in Jaipur and Jodphur, India in December.

The global nature of the tournament aligns seamlessly with the VistaJet brand and its global reach. With a fleet of over 70 super-mid and long range identically branded aircraft, VistaJet guarantees availability from as little as 24 hours notice to its Program members, no matter where in the world they are based.

Wealth-X Institute UHNW Interests, Passions and Hobbies Study 2018

Information
Jennifer Farquhar | T: +44 203 617 3077 | M: +44 7834 335505 |  jennifer.farquhar@vistajet.com

About VistaJet
VistaJet is the first and only global aviation company. On its fleet of over 70 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere. Customers can also request Direct one-off flights through the industry's first end-to-end booking app or a 24/7 global team.

More VistaJet information and news at vistajet.com

About British Polo Day
British Polo Day began in Dubai in 2009 with the aim of creating an invitation-only global platform to build relationships with some of the world's most dynamic and most interesting individuals, by creating distinct experiences in iconic destinations. There have now been over 60 British Polo Days in 16 counties spread over 5 continents with a partner base that remains characterised by 'best in class' across the board and one that now represents over 2,000 years of heritage cumulatively and has raised over $2m for good causes.

More British Polo Day information and news at britishpoloday.com

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/56cba044-2be3-47b2-9bec-2a9f4aada572

http://www.globenewswire.com/NewsRoom/AttachmentNg/9ba067e6-4cf4-412a-944b-b47b0d7ad47a

http://www.globenewswire.com/NewsRoom/AttachmentNg/b5cf5986-bbbb-451e-afe8-c17a7361d007

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum